BAR1 LIFE Stock Australian S.E.

BD1

Pharmaceuticals

End-of-day quote Australian S.E. Other stock markets			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-

06-24	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-17	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI

INOVIQ Ltd is an Australia-based biotechnology company developing diagnostics and therapeutics for cancer. The Company's commercialized products include EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The Company is also advancing clinical-stage diagnostics for the detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumors.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.2050AUD

Average target price

0.7000AUD

Spread / Average Target

+241.46%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

As early as today, start finding the best investment opportunities!

Market Cap	28.86M 20.38M 17.63M 16.46M 15.1M 28.41M 1.94B 193M 75.82M 972M 76.54M 74.86M 3.21B	P/E 2026 *	-5.13x	P/E 2027 *	-5.13x
Enterprise Value	28.86M 20.38M 17.63M 16.46M 15.1M 28.41M 1.94B 193M 75.82M 972M 76.54M 74.86M 3.21B	EV / Sales 2026 *	32.1x	EV / Sales 2027 *	20.6x
Free-Float	66.05%	Yield 2026 *	-	Yield 2027 *	-

06-24	Inoviq Says CAR-Exosome Platform Showed In Vitro Tumor-Killing Activity in Ovarian Cancer; Shares Down 4%	MT
02-17	INOVIQ Ltd Reports Earnings Results for the Half Year Ended December 31, 2025	CI
12-22	INOVIQ Appoints Chief Scientific Officer	MT
12-22	INOVIQ Limited Announces Management Changes, Effective January 12, 2026	CI
12-17	Inoviq says Peter Gunzburg elected to role of chairman	RE
11-27	Inoviq Ltd Elects Peter Gunzburg as Non-Executive Director	CI
11-27	Inoviq says chairman David Williams to step down at year-end	RE
25-10-16	INOVIQ Ltd Announces Appointment of Peter Gunzburg as A Non-Executive Director, Effective 20 October 2025	CI
25-10-12	Inoviq completes A$9.5 million placement	RE
25-10-08	Inoviq Ltd seeks trading halt	RE
25-09-25	INOVIQ Secures Worldwide License for Development, Commercialization of Ovarian Cancer Detection Biomarkers; Shares Jump 5%	MT
25-09-25	Inoviq licences worldwide rights to ovarian cancer biomarker IP from UniQuest	RE
25-08-21	INOVIQ Ltd Reports Earnings Results for the Full Year Ended June 30, 2025	CI

23-07-07	INOVIQ AND PROMEGA ANNOUNCE GLOBAL JOINT MARKETING AGREEMENT FOR EXO-NET EXOSOME ISOLATION AND NUCLEIC ACID PURIFICATION SOLUTIONS	AQ
22-07-26	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - June 2022	PU
22-04-28	INOVIQ : IIQ Appendix 4C & Quarterly Activities Report - March 2022	PU
22-04-05	INOVIQ : Updated Investor Presentation	PU
21-12-06	BARD1 Life Sciences : Application for quotation of securities - BD1	PU

Manager	Title	Age	Since
Leearne Hinch CEO	Chief Executive Officer	-	2016-11-06
Mark Edwards DFI	Director of Finance/CFO	-	2022-11-01
Rebecca Lim CTO	Chief Tech/Sci/R&D Officer	-	2026-01-11

Director	Title	Age	Since
Philip Powell BRD	Director/Board Member	67	2019-06-17
Robert Johnston BRD	Director/Board Member	-	2019-06-17
Geoff Cumming CHM	Chairman	-	2020-07-27

BAR1 LIFE Stock Australian S.E.

Stocks

BD1

Pharmaceuticals

Valuation: BAR1 LIFE

Latest news : BAR1 LIFE

Press Releases: BAR1 LIFE

Managers and Directors: BAR1 LIFE

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAR1 LIFE	-.--%	-.--%	-	-	20.38M
ELI LILLY AND COMPANY	-0.52%	+3.21%	+89.52%	+127.32%	1,057B
JOHNSON & JOHNSON	+0.88%	+1.13%	+49.56%	+49.69%	625B
ABBVIE INC.	+0.89%	-1.95%	+24.23%	+64.44%	435B
ROCHE HOLDING AG	+0.71%	+3.87%	+49.07%	+37.85%	363B
NOVARTIS AG	+0.64%	-0.49%	+33.94%	+40.01%	296B
ASTRAZENECA PLC	+0.39%	-5.83%	+8.92%	+7.85%	249B
AMGEN INC.	+1.51%	+6.69%	+42.58%	+57.57%	222B
NOVO NORDISK A/S	+3.92%	-0.46%	-5.56%	-52.32%	209B
GILEAD SCIENCES, INC.	+1.80%	+2.30%	+11.56%	+66.35%	165B
Average	+1.02%	+0.87%	+33.76%	+44.31%	402.31B
Weighted average by Cap.	+0.66%	+1.22%	+48.72%	+64.63%

	2026 *	2027 *
Net sales	900K 636K 550K 513K 471K 886K 60.49M 6.02M 2.36M 30.32M 2.39M 2.33M 100M	1.4M 989K 855K 799K 733K 1.38M 94.1M 9.37M 3.68M 47.17M 3.71M 3.63M 156M
Net income	-	-
Net Debt	-	-